Co-Diagnostics, Inc.

CODX

$1.16

-2.52%

N/A-$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the ...

Recent News of CODX

PRNewsWireyesterdayNeutral

Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India

Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India.

PRNewsWire3 days agoNeutral

Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base

Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line SALT LAKE CITY, Sept. 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the first international deployment of its Vector Smart® mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito abatement reagents and materials to an overseas United States Air Force ("USAF") base.

PRNewsWire8/18/2026Neutral

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated by the intellectual property law firm Maschoff Brennen in Salt Lake City, Utah. The 90-minute event included discussion of topics such as the significance of recent innovations and challenges surrounding the medical device industry in Utah, the current and future impact of artificial intelligence on the industry, how data interoperability is shaping product development and forecasts for adoption, and what factors are currently shaping companies' strategies in bringing technologies from concept to commercialization.

Seeking Alpha8/13/2026Neutral

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

PRNewsWire8/13/2026Neutral

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled Capabilities SALT LAKE CITY, Aug. 13, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights: Advanced CoMira Diagnostics' manufacturing strategy in the Kingdom of Saudi Arabia through Saudi approval for a manufacturing facility industrial site and execution of a lease agreement in Sudair Industrial City, supporting planned localized production and future commercialization across the Middle East and North Africa (MENA) Expanded commercial outreach through participation in a European trade mission with the Utah Governor's Office and World Trade Center Utah, while showcasing the Co-Dx PCR platform and CE-IVD solutions at ESCMID Global 2026 to engage prospective customers, distributors, and strategic partners Presented the Co-Dx PCR tuberculosis (TB) platform at the Stop TB Partnership Summit in Washington, D.C.

PRNewsWire•yesterday

Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India

Neutral

General

CODX: Neutral

PRNewsWire•3 days ago

Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Neutral

General

CODX: Neutral

Seeking Alpha•8/13/2026

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro ® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration ("FDA") for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument*. The submission follows the Company's previously announced completion of the clinical and analytical performance studies supporting the test.

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument SALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms ("C-CAMP"), an initiative supported by the India Department of Biotechnology.

Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform

PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India SALT LAKE CITY, July 22, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro ® instrument.

Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics.

Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand

Invited by the Stop TB Partnership and the Global Fund to participate as a manufacturer partner Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics SALT LAKE CITY, July 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the United Nations Office for Project Services' (UNOPS) Global Implementation Workshop on Near Point of Care (NPOC) TB Diagnostics in Bangkok, Thailand, July 8-10, 2026. The workshop is intended to bring together national tuberculosis ("MTB" or "TB") programs, national reference laboratories, implementers, researchers, donors, and technical agencies to share early implementation experience with NPOC platforms, to translate the new WHO guidelines on NPOC diagnostics (including tongue swabs and sputum pooling) into national policy and operational plans, and to support countries preparing the NPOC components of their Global Fund GC8 funding requests.

Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026 SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of clinical and analytical performance studies for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument* that the Company currently expects to include in its planned submission package. Completion of these studies represents a significant milestone in preparation of a Dual 510(k) and CLIA Waiver by Application submission to the U.S. Food and Drug Administration ("FDA"), targeted for Q3 2026.

Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement district ("MAD") customer base for the Vector Smart® line of products and services have grown to include MADs in 21 states, with four new full laboratory installs added in June alone. The announcement coincides with Co-Dx hosting a webinar for prospective MAD customers in recognition of National Mosquito Control Awareness Week.

Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding menu of molecular diagnostics products across a key Latin American market SALT LAKE CITY, June 11, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR point-of-care platform*, including the PCR Pro® instrument and associated test kits, advancing the Company's strategy to expand its commercialization network and footprint in Latin America ahead of the platform's market launch, which remains subject to applicable regulatory review and authorization. "We are pleased to continue building on our longstanding relationship in Mexico with a distributor that played an important role in the successful deployment of our molecular diagnostics products during the COVID-19 pandemic," said Dwight Egan, Chief Executive Officer of Co-Diagnostics.

Neutral

General

CODX: Neutral

Supply Chain of CODX

RELATIONS

Upstream

Bio Molecular Systems (BMS)Merck KGaA (MilliporeSigma / Sigma-Aldrich)ETR:MRKThermo Fisher Scientific Inc.NYSE:TMOSynbiotics LtdAmbalal Sarabhai Enterprises Ltd (ASE)BSE:500009

Downstream

CoSara Diagnostics Pvt Ltd (India JV)CoMira Diagnostics (Saudi Arabia JV)Mexico Distributor (Longstanding Partner)American Bio Medica Corporation (ABMC)OTCPINK:ABMCAimil Ltd

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer